Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer

    NEXT STORY
    Global Vaccines Industry Report 2020: Market Projected to Cross $81 Billion by 2027 – Increase in the Adoption of Combination Vaccines in Prevention Strategies by the Government
    PREV STORY
    CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data

    author_avatar
    NASDAQ Market News

    Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market

    author_avatar
    NASDAQ Market News

    In-vitro Diagnostic Services Market worth over $63 billion by 2024: Global Market Insights, Inc.

    In-vitro Diagnostic Services Market By Service Type, By End-user, Regional Outlook (U.S., Canada, Germany, ...

    author_avatar
    NASDAQ Market News